Compare NEON & INAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NEON | INAB |
|---|---|---|
| Founded | 1997 | 2016 |
| Country | Sweden | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 27.9M | 22.9M |
| IPO Year | 1994 | 2020 |
| Metric | NEON | INAB |
|---|---|---|
| Price | $1.38 | $1.96 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $6.00 | $6.00 |
| AVG Volume (30 Days) | ★ 107.0K | 35.9K |
| Earning Date | 03-18-2026 | 03-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 37.88 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $3,108,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $43.34 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.37 | $0.12 |
| 52 Week High | $29.90 | $4.20 |
| Indicator | NEON | INAB |
|---|---|---|
| Relative Strength Index (RSI) | 28.80 | 50.07 |
| Support Level | N/A | $1.52 |
| Resistance Level | $2.01 | $2.15 |
| Average True Range (ATR) | 0.09 | 0.17 |
| MACD | -0.02 | 0.01 |
| Stochastic Oscillator | 6.24 | 47.06 |
Neonode Inc provides optical sensing solutions for contactless touch, and gesture sensing and also provides software solutions for machine perception that feature machine learning algorithms to detect and track persons and objects in video streams from cameras and other types of imagers. It markets and sells its solutions to customers in many different markets and segments including, office equipment, automotive, industrial automation, medical, military, and avionics. The company geographically operates in the United States, Japan, South Korea, Germany, Sweden, China, and other regions. A majority of its revenue is generated from Japan.
IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of gamma-delta T cell product candidates for solid and liquid tumors, by employing allogeneic, autologous, and genetically modified gamma-delta T cells. Its product candidates include INB-400, for the treatment of newly diagnosed glioblastoma, or GBM, INB-100 for the treatment of patients with high-risk leukemias undergoing hematopoietic stem cell transplantation, and other product candidates such as INB-200, INB-300, and INB-500.